Centene Corporation (CNC) and Molina Healthcare (MOH) operate at the heart of the managed care sector. Both companies focus heavily on Medicaid and other government-funded programs, so their results move in tandem with policy changes, reimbursement rates, and medical-cost trends. A direct comparison helps clarify how two similar business models are positioned differently in the current environment.
Centene stands as the largest Medicaid managed care organization in the United States, with additional exposure to Medicare, commercial lines, and pharmacy services. The stock has rallied sharply in recent weeks after the midterm elections, reflecting greater investor certainty around Medicaid and Affordable Care Act funding. Shares have more than doubled from the 52-week low near $31 and now sit close to multi-year highs.
Fundamentals support the move. Centene posted better-than-expected third-quarter results with adjusted EPS above consensus and raised full-year guidance. The health benefits ratio has improved, prompting several analysts to lift price targets. A broad consensus Buy rating backs the sentiment. On the other side, a Department of Justice matter tied to a whistleblower lawsuit and ongoing exposure to medical-cost trends remain points to watch. I also checked this using Tickeron’s AI Trend Prediction Engine to see how the stock’s momentum stacks up against peers.
Molina Healthcare concentrates on Medicaid, Medicare, and Marketplace coverage for lower-income populations, with Medicaid representing the bulk of premium revenue. After a sharp drop in early February 2026 following a fourth-quarter 2025 loss, the stock has climbed roughly 70% from its February low. A first-quarter profit beat and solid third-quarter results helped the rebound.
In the latest quarter, Molina beat both revenue and adjusted EPS forecasts while reaffirming full-year guidance of at least $5.25 per share. Management views current Medicaid margins as a likely trough and outlined early 2027 EPS building blocks above $9.50. Membership has contracted about 6% year over year due to redeterminations and work requirements, and the company is exiting its underperforming Medicare Advantage Prescription Drug line while reducing its Marketplace presence. These shifts introduce near-term volatility.
Scale sets the two apart most clearly. Centene’s market capitalization is about three times larger, and its revenue base offers broader diversification across Medicaid, Medicare, and commercial segments. Molina remains more concentrated in Medicaid, where individual contracts and rate decisions carry greater weight.
Momentum patterns also diverge. Centene’s gains have been steadier, supported by the Buy consensus and rising targets. Molina’s advance has been strong yet more uneven, resting on expectations of margin recovery rather than immediate earnings growth. Risk profiles differ too: Centene contends with regulatory scrutiny and elevated medical costs, while Molina faces membership attrition and contract transitions. Valuation-wise, Centene trades at a modest forward multiple with improving margins; Molina’s trailing P/E is not meaningful after its recent loss, so investors are effectively pricing in a 2027 recovery that has yet to appear in results.
Based on the observable factors, Tickeron’s AI would likely rank CNC ahead of MOH right now. Centene shows more consistent relative performance, steadier earnings momentum, and greater resilience from its size and diversification. Molina’s margin-trough narrative is intriguing but hinges on forward assumptions not yet validated in reported numbers. On trend consistency and market positioning, Centene currently looks like the more probable setup.
When evaluating names like these, I often review Tickeron’s Trending AI Robots to see how automated strategies are positioned across the broader market. The page surfaces bots with timely setups and performance records, offering a useful data-driven layer alongside traditional analysis.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
The 10-day moving average for MOH crossed bullishly above the 50-day moving average on October 15, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 11 of 13 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 85%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 37 of 52 cases where MOH's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 71%.
The Momentum Indicator moved above the 0 level on November 10, 2026. You may want to consider a long position or call options on MOH as a result. In 57 of 84 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 68%.
MOH moved above its 50-day moving average on October 30, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +1.70% 3-day Advance, the price is estimated to grow further. Considering data from situations where MOH advanced for three days, in 215 of 317 cases, the price rose further within the following month. The odds of a continued upward trend are 68%.
The Aroon Indicator entered an Uptrend today. In 148 of 222 cases where MOH Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 67%.
The 10-day RSI Indicator for MOH moved out of overbought territory on November 05, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 33 similar instances where the indicator moved out of overbought territory. In 18 of the 33 cases, the stock moved lower in the following days. This puts the odds of a move lower at 55%.
The Moving Average Convergence Divergence Histogram (MACD) for MOH turned negative on November 09, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 47 similar instances when the indicator turned negative. In 32 of the 47 cases the stock turned lower in the days that followed. This puts the odds of success at 68%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MOH declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 65%.
MOH broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron PE Growth Rating for this company is 1 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 35 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 44 (best 1 - 100 worst), indicating fairly steady price growth. MOH’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 90 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 99 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.616) is normal, around the industry mean (3.520). MOH's P/E Ratio (1306.188) is considerably higher than the industry average of (126.353). Projected Growth (PEG Ratio) (0.880) is also within normal values, averaging (0.786). Dividend Yield (0.000) settles around the average of (0.009) among similar stocks. P/S Ratio (0.233) is also within normal values, averaging (0.569).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MOH’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a provider of health care services to persons eligible for Medicaid
Industry ManagedHealthCare